Announcement

International advanced course on clinical management of drug-resistant tuberculosis for WHO Europe Region countries, 2016

Objective
Update knowledge of the participants on the latest global developments in M(X) DR-TB, as well develop necessary skills for M(X) DR-TB case management in their respective countries.

After completing the course, participants will be able to:
- understand the DOTS strategy as the key to prevent MDR-TB; programmatic management and different components of MDR-TB, as well as milestones and activities to achieve WHO End TB Strategy;
- describe how Mycobacterium TB can be detected and resistance to anti-TB drugs determined. Use WHO endorsed molecular test to detect TB DNA and mutations associated with resistance and use in clinical practice;
- apply effective case finding and diagnosis strategies to diagnose rifampicin-resistant TB, MDR-TB and XDR-TB; access diagnostic test results for use in clinical practice; decide of enrolment in treatment;
- apply principles of DR-TB treatment for adults and children, MDR-TB/HIV co-infection;
- apply WHO approaches to the introduction of Bedaquiline and Delamanid under programmatic conditions; learn clinical issues in new drug introduction;
- understand WHO policy on pharmacovigilance for anti-TB drugs: use of different methods; describe methods for active pharmacovigilance when new and repurposed drugs and novel regimens are used;
- describe the measures to promote patient safety, improving quality of care during proper management of adverse effects caused by second-line anti-TB drugs;
- provide patients treatment success monitoring according to MDR-TB standards of care, identify treatment failure and change treatment strategy, manage treatment interruption and default;
- describe TB/HIV collaborative activities, understand the early diagnosis of drug-resistant TB and HIV, prompt initiation of appropriate second line anti-TB drugs and antiretroviral treatment;
- apply patient centered care and prevention, ensure their quality of life, decrease catastrophic costs for patients during treatment, delivery of social, psychosocial support, support to human rights, ethical standards, and confidentiality.

Target audience
Clinicians, responsible for the clinical management of DR-TB.

Venue
WHO CC Latvia of Riga East Clinical University Hospital, Centre of TB and Lung Diseases, address: Upeslejas, Stopinu district, LV-2118, LATVIA, Tel.: +371 67048246, e-mail: info@ltbf.lv.

Duration and language
Course will last for 9 working days (including Saturday) with 8* 45 min lectures per day;
Course is available in Russian and English (according to schedule).

Registration:
Please send your application form to e-mail address: info@ltbf.lv. For visa support fill in visa section in application form and attach your passport copy to your registration.

Contact information:
Program: Dr Vaira Leimane, Head of WHO CC Latvia, e-mail: vaira@ltbf.lv, Tel. + 371 6704824;
Administrative assistance, registration, hotel, visa support, training fee: Ms. Liga Rusmane, Tuberculosis Foundation of Latvia, e-mail: info@ltbf.lv; liga.rusmane@gmail.com, Tel. +371 297742677